Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

Chicago, IL – June 10, 2025 – Today, Zacks Equity Research discusses Sandoz SDZNY, Teva Pharmaceuticals TEVA and Viatris VTRS ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Regeneron (REGN) performed poorly. REGN stock entered a prolonged downtrend, despite no major news that would explain the decline. Last Friday, May 30, Regeneron and its drug development partner ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced st ...

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...